TIGLUTIK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tiglutik, and when can generic versions of Tiglutik launch?
Tiglutik is a drug marketed by Italfarmaco Sa and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in TIGLUTIK is riluzole. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the riluzole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tiglutik
A generic version of TIGLUTIK was approved as riluzole by IMPAX LABS on January 29th, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TIGLUTIK?
- What are the global sales for TIGLUTIK?
- What is Average Wholesale Price for TIGLUTIK?
Summary for TIGLUTIK
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for TIGLUTIK |
| What excipients (inactive ingredients) are in TIGLUTIK? | TIGLUTIK excipients list |
| DailyMed Link: | TIGLUTIK at DailyMed |
US Patents and Regulatory Information for TIGLUTIK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Italfarmaco Sa | TIGLUTIK KIT | riluzole | SUSPENSION;ORAL | 209080-001 | Sep 5, 2018 | AB | RX | Yes | Yes | 8,765,150 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
